Category: Advocacy

ARC Creates Pathway for Patient Engagement with FDA
Much has been said about the need to put patients at the center of drug development. The Amyloidosis Research Consortium (ARC), is doing just that. The FDA's Patient-Focused Drug Development initiative is a commitment under the fifth authorization of the...
Read More
Blazing the Trail for Amyloidosis in Brazil
Guilherme José Jucá Calheiros carried the Olympic torch in Maceio (AL) Brazil. Guilherme is diagnosed with ATTR Familial Amyloidosis (FAP), which is a rare autosomal dominant amyloidosis disease caused by the deposition of abnormal transthyretin that results from a gene mutation....
Read More
Advocates Take on The Hill
"By sharing my story, they not only learned about amyloidosis; they also heard about our community's desperate need for approved treatments and pledged their support" I attended Rare Disease Week on Capitol Hill (February 29th– March 4th) as a Rare...
Read More
Patient Forum with FDA
The Amyloidosis Research Consortium (ARC) held an amyloidosis patient forum with the FDA in Silver Spring, MD on November 16. 2015.  It was an historic, standing room only event for our community. The room was filled with patients that were...
Read More
Join us and the FDA for a patient focused meeting on amyloidosis
Amyloidosis Research Consortium is hosting a critical meeting with the FDA in Bethesda on November 16th, 2015. This is an unprecedented opportunity: patients can inform the FDA about their experience and unmet needs. At the FDA's request, amyloidosis experts will...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization